Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Reports from Nanjing Medical University describe recent advances in cancer vaccines
March 19th, 2008
New investigation results, 'Immunization with a recombinant GnRH vaccine conjugated to heat shock protein 65 inhibits tumor growth in orthotopic prostate cancer mouse model,' are detailed in a study published in Cancer Letters. "We have previously shown that anti-GnRH antibodies responses can be induced by synthetic GnRH3-hinge-MVP peptide. In this study, GnRH3-hinge-MVP of conjugation to heat shock protein 65 was used as an adjuvant-free vaccine to assess the therapeutic effects of GnRH immunoneutralisation on tumor development in the mice model," scientists in Nanjing, People's Republic of China report. "Compared with mice treated with Hsp65 and PBS, mice of...
Source: Vaccine Weekly (2008-03-19)
|
